(EN) 2109820 9319084 PCTABS00025 The present invention resides in the refolding of recombinantly produced IGF-I expressed in prokaryotic cells, particularly bacteria, to render biologically active IGF-I, and to methods of isolating correctly refolded IGF-I from incorrectly refolded IGF-I. The present invention also resides in pharmaceutical compositions containing IGF-I and in methods of treating a patient having an IGF associated condition. The present invention also relates to the conversion of met-IGF-I to IGF-I.
|